Literature DB >> 31062563

Use of botulinum toxin A in children with cerebral palsy.

Anne Elisabeth Ross Raftemo, Arani Mahendran, Sandra Julsen Hollung, Reidun Birgitta Jahnsen, Stian Lydersen, Torstein Vik, Guro Lillemoen Andersen.   

Abstract

BACKGROUND: For more than 20 years, intramuscular injections of botulinum toxin A have been an established treatment for spasticity in children with cerebral palsy. We investigated the proportion of children with cerebral palsy who receive such treatment in Norway and the guidelines that apply to the treatment. MATERIAL AND
METHOD: Data from the five-year registration in the Cerebral Palsy Registry of Norway were used to investigate the proportion of children with cerebral palsy born in the period 1999-2010 treated with botulinum toxin A, and whether there were any variations in the proportion of children treated between the habilitation centres. We conducted an online survey to identify the treatment guidelines that were applied in all of the 21 habilitation centres.
RESULTS: A total of 1 414 children (average age 6.3 years) were included, of whom 775 (55 %) had been treated with botulinum toxin A. The proportion of children who received treatment varied considerably between the habilitation centres (38-80 %; p < 0.001). The maximum dose of botulinum toxin A per treatment per patient was 200-600 units of Botox. Five centres reported to have written guidelines for the treatment indication.
INTERPRETATION: The proportion of children with cerebral palsy who are treated with botulinum toxin A varies considerably between Norwegian habilitation centres.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31062563     DOI: 10.4045/tidsskr.18.0554

Source DB:  PubMed          Journal:  Tidsskr Nor Laegeforen        ISSN: 0029-2001


  1 in total

1.  Inequalities in pharmacologic treatment of spasticity in Sweden - health economic consequences of closing the treatment gap.

Authors:  Annabelle Forsmark; Linda Rosengren; Per Ertzgaard
Journal:  Health Econ Rev       Date:  2020-02-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.